Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cell cycle regulation of human pancreatic cancer by tamoxifen.
Robinson EK, Grau AM, Evans DB, Smid CM, Chiao PJ, Abbruzzese JL, Grimm EA. Robinson EK, et al. Among authors: grau am. Ann Surg Oncol. 1998 Jun;5(4):342-9. doi: 10.1007/BF02303498. Ann Surg Oncol. 1998. PMID: 9641456
Prognostic factors in resectable pancreatic cancer: p53 and bcl-2.
Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Cleary KR, Hallin PA, Chiao PJ, Abbruzzese JL, Evans DB. Bold RJ, et al. Among authors: grau am. J Gastrointest Surg. 1999 May-Jun;3(3):263-77. doi: 10.1016/s1091-255x(99)80068-7. J Gastrointest Surg. 1999. PMID: 10481119
Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer.
Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol JA. Chakravarthy AB, et al. Among authors: grau am. Clin Cancer Res. 2006 Mar 1;12(5):1570-6. doi: 10.1158/1078-0432.CCR-05-2304. Clin Cancer Res. 2006. PMID: 16533783
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. Jovanović B, et al. Among authors: grau am. Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7. Clin Cancer Res. 2017. PMID: 28270498 Free PMC article. Clinical Trial.
Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL, Chen SC, Murray E, Johnson CA, Crandall H, O'Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A. Shattuck-Brandt RL, et al. Clin Cancer Res. 2020 Jul 15;26(14):3803-3818. doi: 10.1158/1078-0432.CCR-19-1895. Epub 2020 Mar 31. Clin Cancer Res. 2020. PMID: 32234759 Free PMC article.
44 results